See more : Getchell Gold Corp. (GTCH.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Inventiva S.A. (IVA.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inventiva S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Tuscan Holdings Corp. II (THCAW) Income Statement Analysis – Financial Results
- Novacyt S.A. (NCYT.L) Income Statement Analysis – Financial Results
- HEICO Corporation (HEI-A) Income Statement Analysis – Financial Results
- Gseven Co., Ltd. (2937.TWO) Income Statement Analysis – Financial Results
- Kina Securities Limited (KSL.AX) Income Statement Analysis – Financial Results
Inventiva S.A. (IVA.PA)
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.48M | 12.18M | 4.19M | 372.00K | 7.00M | 3.20M | 6.52M | 9.45M | 4.87M | 3.28M | 3.06M |
| Cost of Revenue | -23.00K | 995.00K | 1.02M | 846.00K | 0.00 | 967.00K | 1.24M | 1.49M | 1.40M | 1.52M | 1.68M |
| Gross Profit | 17.50M | 11.18M | 3.18M | -474.00K | 7.00M | 2.23M | 5.28M | 7.96M | 3.47M | 1.76M | 1.38M |
| Gross Profit Ratio | 100.13% | 91.83% | 75.75% | -127.42% | 100.00% | 69.75% | 81.05% | 84.27% | 71.18% | 53.59% | 45.11% |
| Research & Development | 110.01M | 60.47M | 48.45M | 23.72M | 33.79M | 31.64M | 26.73M | 22.14M | 19.64M | 16.28M | 13.75M |
| General & Administrative | 13.85M | 12.91M | 11.16M | 8.50M | 4.51M | 4.51M | 4.09M | 3.25M | 3.11M | 2.65M | 2.71M |
| Selling & Marketing | 1.76M | 2.58M | 364.00K | 563.00K | 8.00K | 9.00K | 37.78K | 50.56K | 112.70K | 247.32K | 325.57K |
| SG&A | 15.61M | 15.50M | 11.52M | 9.06M | 4.51M | 4.52M | 4.12M | 3.30M | 3.22M | 2.90M | 3.04M |
| Other Expenses | -5.43M | -6.68M | -3.66M | -2.69M | -2.09M | 257.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 120.19M | 69.29M | 56.31M | 30.09M | 36.21M | 36.42M | 26.99M | 21.49M | 19.75M | 16.75M | 15.53M |
| Cost & Expenses | 120.19M | 69.29M | 56.31M | 30.09M | 36.21M | 36.42M | 26.99M | 21.49M | 19.75M | 16.75M | 15.53M |
| Interest Income | 991.00K | 390.00K | 5.48M | 226.00K | 157.00K | 120.00K | 276.62K | 230.18K | 227.63K | 273.84K | 42.65K |
| Interest Expense | 5.22M | 707.00K | 2.64M | 66.00K | 3.00K | 4.00K | 5.32K | 7.55K | 6.06K | 2.94K | 630.00 |
| Depreciation & Amortization | 2.53M | 1.68M | 927.00K | 1.01M | 1.46M | 949.00K | 1.24M | 1.49M | 1.30M | 1.23M | 1.38M |
| EBITDA | -102.04M | -57.11M | -52.27M | -31.78M | -28.36M | -32.04M | -22.00M | -11.14M | -13.91M | -12.43M | -11.42M |
| EBITDA Ratio | -583.86% | -468.92% | -1,111.99% | -7,988.71% | -392.90% | -969.50% | -287.82% | -104.86% | -268.39% | -349.37% | -337.41% |
| Operating Income | -102.71M | -57.11M | -52.11M | -29.72M | -30.31M | -33.25M | -20.92M | -13.02M | -15.51M | -13.47M | -12.47M |
| Operating Income Ratio | -587.68% | -468.92% | -1,242.58% | -7,988.71% | -433.15% | -1,040.13% | -320.76% | -137.83% | -318.17% | -410.22% | -406.81% |
| Total Other Income/Expenses | -7.11M | 2.82M | 2.84M | -3.90M | 95.00K | -111.00K | 278.00K | 460.23K | 486.14K | 745.10K | 748.35K |
| Income Before Tax | -109.82M | -54.29M | -49.27M | -33.62M | -30.22M | -33.36M | -20.64M | -12.56M | -15.02M | -12.72M | -11.72M |
| Income Before Tax Ratio | -628.36% | -445.80% | -1,174.82% | -9,037.63% | -431.79% | -1,043.57% | -316.49% | -132.96% | -308.20% | -387.52% | -382.39% |
| Income Tax Expense | 607.00K | -20.00K | 364.00K | -2.00M | 4.00K | 253.00K | -3.41M | -5.51M | -6.20M | -5.23M | -4.58M |
| Net Income | -110.43M | -54.27M | -49.64M | -31.62M | -30.22M | -33.62M | -17.23M | -7.05M | -8.82M | -7.49M | -7.13M |
| Net Income Ratio | -631.84% | -445.64% | -1,183.50% | -8,500.81% | -431.85% | -1,051.49% | -264.22% | -74.59% | -181.00% | -228.26% | -232.82% |
| EPS | -2.43 | -1.31 | -1.27 | -0.93 | -1.28 | -1.64 | -1.11 | -0.45 | -0.88 | -0.75 | -0.71 |
| EPS Diluted | -2.43 | -1.31 | -1.27 | -0.93 | -1.28 | -1.64 | -1.11 | -0.45 | -0.88 | -0.75 | -0.71 |
| Weighted Avg Shares Out | 45.35M | 41.45M | 39.17M | 33.87M | 23.52M | 20.54M | 15.52M | 15.68M | 10.03M | 10.03M | 10.03M |
| Weighted Avg Shares Out (Dil) | 45.35M | 41.45M | 39.17M | 33.87M | 23.52M | 20.54M | 15.52M | 15.74M | 10.03M | 10.03M | 10.03M |
Source: https://incomestatements.info
Category: Stock Reports